This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dinney, C. P. N. Articles by Killion, J. J. Search for Related Content PubMed PubMed Citation Articles by Dinney, C. P. N. Articles by Killion, J. J.

Immunotherapy of Murine Renal Adenocarcinoma by Systemic Administration of Liposomes Containing the Synthetic Macrophage Activator CGP 31362 or CGP 19835A in Combination with Interleukin 2 or -Interferon¹

Department of Cell Biology [C. P. N. D., T. U., I. J. F., J. J. K.] and Department of Urology [A. C. v. E.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

The purpose of these experiments was to evaluate the possibility that the systemic administration of liposomes containing synthetic macrophage activation CGP 31362 or CGP 19835 in mice which were simultaneously receiving injections of -interferon or interleukin 2 would lead to enhanced regression of spontaneous lung metastases produced by syngeneic renal adenocarcinoma. The kidneys of BALB/c mice were given injections of renal adenocarcinoma cells, and 10 days later the kidney with local tumor was surgically resected. These mice were then given injections i.v. with liposomes and with -interferon (s.c.) or interleukin 2 (i.p.). Systemic administration of MLV-CGP 31362 and MLV-CGP 19835A significantly reduced the number of lung metastases in nephrectomized mice. Both lung tumor burden and regional recurrence were further reduced by the s.c. injection of -interferon or i.p. injection of interleukin 2. Long-term survivors were observed only in the groups of animals treated with liposomes containing macrophage activators and with lymphokines. Evaluation of host responsiveness to this immunotherapy revealed in situ activation of alveolar macrophages by administration of MLV-CGP 31362 or MLV-CGP 19835A, which was enhanced in mice also treated with interleukin 2. Normal levels of natural killer cell activity were reduced in the spleens of tumor-bearing mice but were restored subsequent to treatment with MLV-CGP 31362. These results indicate the potential usefulness of treating metastatic renal cell carcinoma by systemic administration of liposomes containing synthetic macrophage activators in combination with parental injections of lymphokines.

¹ Supported in part by Core Grant CA-16672 and Grant R35-CA 42107 from the National Cancer Institute, NIH.

² To whom requests for reprints should be addressed, at The University of Texas M. D. Anderson Cancer Center, Department of Cell Biology, 1515 Holcombe Boulevard, Box 173, Houston, TX 77030.

Received 9/20/91. Accepted 12/13/91.